Baird also maintained a Buy rating on the stock with a $300.00 price target. The company has a one-year high of $268.30 and a one-year low of $163.35. Currently, Biogen has an average volume of 1.24M.

Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Biogen (BIIB – Research Report) and keeping the price target at ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting ...

Trace Neuroscience, which launched this week with $101 million, benefited from last year’s approval of Qalsody. Its CEO spoke ...

Shares of Biogen Inc. BIIB slid 1.48% to $165.79 Wednesday, on what proved to be an all-around favorable trading session for ...

The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26. Biogen Inc. has a one year low of $170.71 and a one year high of $268.30. The company has a ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

and is pre-revenue for the part of the business that actually gives the company such a high valuation. Enovix is trying to commercialize longer-lasting and better-performing batteries for smartphones.

There's also the Super Res Zoom feature at work. Here's what each feature does and how they work together to produce high-quality recordings at 30x zoom. Super Res Zoom Video uses Google's machine ...